Open Access

Intracranial non‑myxoid angiomatoid fibrous histiocytoma with EWSR1‑CREB1 transcript fusion treated with doxorubicin: A case report

  • Authors:
    • Louis Garnier
    • Tanguy Fenouil
    • Daniel Pissaloux
    • Roxana Ameli
    • François Ducray
    • David Meyronet
    • Jerome Honnorat
  • View Affiliations

  • Published online on: May 9, 2021     https://doi.org/10.3892/mco.2021.2293
  • Article Number: 131
  • Copyright: © Garnier et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Angiomatoid fibrous histiocytoma (AFH) is a rare soft tissue tumor that has only been reported in the central nervous system in case reports. After surgery, patients exhibit tumor recurrence. Pathological diagnosis of AHF remains difficult, especially in sites other than skin. AFH can harbor characteristic translocations implying that the Ewing sarcoma breakpoint region 1 gene (EWSR1) fuses with the transcription factor cyclic AMP response element binding (CREB) family genes. Doxorubicin is a chemotherapy that has previously been used successfully in two metastatic soft tissue AFH cases but never in intracranial AFH. The present report describes a case of an adult with a progressive classical intracranial non‑myxoid AFH with ESWR1‑CREB1 transcript fusion 4 years after surgery. The patient was treated with doxorubicin as a single agent chemotherapy. This treatment resulted in a prolonged stable disease 15 months after treatment discontinuation. This is the first reported case of a treatment with doxorubicin in an adult with progressive intracranial AFH with ESWR1‑CREB1 transcript fusion which was sustained after treatment discontinuation.

Introduction

Chromosomal translocations resulting in gene fusions are one mechanism underlying tumorigenesis, and some are more frequent in certain cancer entities. The Ewing sarcoma breakpoint region 1 gene (EWSR1), found on chromosome 22q12.2, has a tendency to fuse with the transcription factor cyclic AMP response element binding (CREB) family genes like CREB1, cAMP response element modulator (CREM), or activating transcription factor 1 (ATF1) (1,2). A group of neoplasms are associated with EWSR1-CREB1 and/or EWSR1-ATF1 gene fusions, including angiomatoid fibrous histiocytoma (AFH) but also, clear cell sarcoma, clear cell sarcoma-like tumor of the gastrointestinal tract, primary pulmonary myxoid sarcoma, hyalinizing clear cell carcinoma of the salivary gland, and soft tissue myoepithelial tumor (3). AFH is a rare soft tissue tumor described initially as ‘angiomatoid malignant fibrous histiocytoma’ by Enzinger in 1979(4). It is now described as an indolent tumor with a favorable prognosis by the 2013 World Health Organization classification (5). It is a rare tumor of soft tissue (<0.5%) and mostly occurs superficially, in the extremities of children and young adults (6). Most AFHs are indolent, with a 15 percent regional recurrence rate and a metastatic rate <5%, most frequently involving regional nodes (7). Pathological diagnostic of AHF remain difficult, especially in other sites than skin. As immunohistochemical phenotype is not specific, molecular analysis is useful to confirm the diagnosis and distinguish this entity from likeness tumors. AFH is associated with 3 characteristic translocations: t(2;22)(q33;q12) EWSR1/CREB1 being the most common, t(12;22)(q13;q12) EWSR1/ATF1, and t(12;16)(q13;p11) FUS/ATF1 (3,8). The intracranial location represents a rare primary site, with six conventional AFH cases reported (9-13) and fifteen myxoid AFH (14-23) described as a novel tumor entity. The EWSR1/CREB1 fusion is reported in the myxoid variant but never in the classical non-myxoid component. None of the patients received chemotherapy for this lesion. Herein we describe a case of a classical intracranial non-myxoid AFH with ESWR1-CREB1 transcript fusion treated with doxorubicin as a single agent chemotherapy, inducing a prolonged stable disease fifteen months after treatment discontinuation.

Case report

Clinical history and histological findings

A 40-year-old male referred to the emergency department in 2012 for an intracranial hypertension syndrome with headaches and diplopia. Otherwise, his personal and familial medical clinical history was unremarkable. The magnetic resonance imaging (MRI) of the brain revealed a suspicious lesion of the splenium of the corpus callosum and the pineal region, with hypointense T1 signal, hyperintense T2 signal, and with strong enhancement following gadolinium administration. The lesion was associated with bi-parietal edema. Large increase in lipid and choline without apparent necrosis were showed on spectrometry. There was no sign of neoangiogenesis. The original diagnosis was thought to be lymphoma. He had three needle biopsies between 2012 and 2014 but none of them confirmed this diagnosis. He was then started on corticosteroids but the symptoms got worse with seizures, papillary edema, right homonymous hemianopsia, and agnostic alexia requiring a ventriculoperitoneal shunt. Finally, in March 2014, the patient underwent a left parieto-occipital craniotomy and a subtotal (60%) resection (Fig. 1). The surgical approach was decided because of the retrospenial origin of the tumor and the inferior repulse of the deep venous system. Postoperatively, the patient maintained a right homonymous hemianopsia. He was started on radiation therapy for a total planned dose of 36 grays distributed into 20 sessions, but stopped after 12 sessions for his convenience (i.e. radiotherapy risks and consequences). Chemotherapy was not added to the treatment because of the lack of evidence of its benefits in this case.

From tumor specimens obtained after fine needle biopsy and after surgery, several formalin-zinc fixed paraffin-embedded (FFPE) blocks and Hematoxylin-Eosin-Saffron stained slides were submitted to histological examination after obtaining written informed and signed consent. It revealed a pathological tissue dominated by thick organized collagen fibers mixed with spindle or epithelioid cells. The nuclei were bland with open chromatin resembling those of macrophages or histiocytes (Fig. 2A and B). There was no pseudo syncytial growth pattern. The tumor exhibit large blood-filled pseudo-vascular spaces (Fig. 2A). Lympho-plasmocytic cuffs as well as thick fibrous pseudocapsule were not seen anymore compared to the second and third biopsy where they were respectively present (Fig. 2C and D). There was no myxoid feature nor necrosis, and no mitosis. Immunohistochemically was carried out on 4-µm-thick FFPE tissue section using UltraView Ventana Universal DAB Detection Kit® (F. Hoffmann-La Roche AG, Switzerland). There was only cytoplastic diffuse staining for desmin, patchy staining for EMA and CD68. The Ki-67 labeling index was low (<7%) (Fig. 3A-C). Fluorescence in situ hybridization (FISH) analysis was performed on tumoral nuclei of paraffin embedded 4-µm-sections using ZytoLight FISH-Tissue Implementation Kit with EWSR1 Dual Color Break Apart Probe (Z-2096-50; ZytoVision), specific for EWSR1 at 22q12.2. The number of orange and green dots were then counted (centromeric probe in 5' to the breakpoint and telomeric probe in 3' to the breakpoint, respectively), both into intron 4 of EWSR1, after DNA were counterstained with DAPI, using a fluorescence microscope. Fifty non-overlapping intact nuclei were examined for EWSR1 rearrangement. Eighty percent of them presented in this case a split signal also called break apart signal meaning that separated orange and green dots or single orange dots were seen consistent with a EWSR1 rearrangement (>20% of rearranged nuclei) (Fig. 3D). To look for its fusion partner, a retrotranscriptase-quantitative polymerase chain reaction was then performed in two different molecular departments on FFPE and frozen tissue and confirmed the presence of EWSR1/CREB1 fusion transcript. Diagnosis of classical non-myxoid angiomatoid fibrous histiocytoma with the fusion transcript EWSR1/CREB1 was made by the association of morphological, immunohistochemical and molecular data (5).

Patient management and outcomes

The patient was monitored for four years until MRI demonstrated tumor progression. The last MRI before progression in August 2017 showed a lesion of 35x28x29 mm.

On the MRI of April 2018, the lesion of the pineal region was heterogeneous and measure 40 mm of height, 27 mm of anteroposterior length, and 38 mm of width. It had a hypointense T1 signal, heterogeneous hyperintense T2 signal, and strong patchy enhancement following gadolinium administration. There were some cystic components, with the largest in the right anterior superior part with a diameter of 26 mm (Fig. 1). There was also peritumoral edema. At this time, surgical resection was considered too risky without possibility of complete removal and the patient could not be re-irradiated. The interdisciplinary tumor board decided to treat him as if he had a sarcoma-like tumor. In September 2018, as the tumor was still on progression (Fig. 1), he was started on intravenously doxorubicin 60 mg/m² every three weeks for a total of seven injections. Less than a month after treatment cessation, the patient was neurologically stable and brain MRI showed a <50% decrease in tumor size, considered as stable disease by the Response Assessment in Neuro-Oncology criteria (Fig. 1). Toxicities were measured by the Common Terminology Criteria for Adverse Events v5.0. The patient had a grade III constipation requiring a short-term hospitalization and a treatment with osmotic laxatives and mechanical removal. Otherwise, treatment was well tolerated; by the end, he had grade II alopecia, grade I asthenia, anorexia, and oral mycosis treated with oral bicarbonate. He had no feared anthracycline complication, meaning neither cardiac failure nor hepatotoxicity. Six months after stopping doxorubicin, he recovered from toxicities and MRI showed no signs of progression. Fourteen months after doxorubicin discontinuation in March 2020, MRI and neurological examination showed stable disease (Fig. 1). He still had some mild blurred vision and alexia. Although he was not cured from the disease, the tumor's progression was stopped and both his neuro-cognitive functions and quality of life were preserved.

Discussion

To our knowledge, this is the first case of a patient with classical non-myxoid intracranial AFH treated with single chemotherapy inducing prolonged stable disease. Even if the location is extremely rare, AFH was here confirmed by the integration of radiological, morphological and immunohistochemical data with the molecular analysis. The latter demonstrated the original EWSR1-CREB1 fusion, heretofore only described in intracranial myxoid mesenchymal variant. Indeed, even if EWSR1-CREB1 is the most frequently described fusion transcript in this entity (24), it is the first reported description in intracranial classical AFH. Most soft tissue AFH are indolent with 15 percent risk of local recurrence and less than 5 percent risk of metastases, predominantly to regional lymph nodes (7,25,26). It accounts for 0.3% of all soft tissue tumors and usually occurs in children and young adult (6). The intracranial location is extremely rare and only cases reports are described. This tumor has been reported in twenty-one previous instances: Six conventional AFH (9-13) and fifteen myxoid AFH (14-23). Characteristics of these tumors and their outcomes are listed in Table I. Unlike the present case, medium reported age at diagnosis is 26-year-old with a female predominance. Long-term outcomes (<1 year) are not available in 11 cases but the recurrence rate for the others is 60% (9-19,23). The scarcity of this location makes the diagnosis difficult. When utilizing imaging results, the most frequently established diagnosis is meningioma or lymphoma (12,18,23). Histologically, the diagnostic of intracranial AFH is difficult: The tumor is well delimited with lobulated or multinodular borders and thick fibrous pseudocapsule. In up to 80% of tumors, dense lymphoplasmacytic infiltrate or cuffs can be seen, resembling those of schwannoma. Multifocal hemorrhage is seen in most cases, forming blood-filled cystic spaces of variable size. Mostly half of the AFHs express desmin, without positivity for myogenin or MyoD1. Many express EMA and CD68(3). In our case, diagnosis was complicated due to repeated intracranial biopsy sampling of the tumor that not only gives little insights of its morphological characteristics but also induces changes in morphological features (like fibrosis, hemorrhage or tissue distortion). This tumor expressed desmin, EMA and CD68, which finally made us suspect AFH diagnosis and ask for the molecular analyses that confirmed it (25).

Table I

Comprehensive list of reported cases of angiomatoid fibrous histiocytoma (with myxoid component or not) and their treatment with reported outcomes.

Table I

Comprehensive list of reported cases of angiomatoid fibrous histiocytoma (with myxoid component or not) and their treatment with reported outcomes.

AFHAuthorsAge (years)/sexLocationSymptoms/signs (clinical features)MRISurgeryIHCGenetic markerTreatment post-surgeryTime to recurrenceTotal follow up/recurrence(Refs.)
Conventional AFHDunham et al, 200825/MOccipital lobeVisual problems, headachesCystic component, heterogeneously enhancementGTREMA+, desmin+ EWSR1/ATF1NoneNMNM(9)
 Ochalski et al, 201035/MTemporal lobeHeadaches, facial weaknessMinimal enhancementGTRDesmin+, EMA NMRearranged EWSR1 geneGKSa0.8 months49 months/multipleb(10)
 Hansen et al, 201517/FParieto-occipital lobeHeadachesHeterogeneously enhancement, edemaGTREMA+, desmin+NegativeNoneNA3 months/none(11)
 Alshareef et al, 201658/FPorous trigeminusFacial weaknessHeterogeneously enhancement, edemaGTRNMRearranged EWSR1 geneNoneNA6 months/none(12)
 Konstantinidis et al, 201913/FFrontal lobeHeadachesCystic component, enhancement, edemaGTRDesmin+, EMA NM EWSR1/ATF1None5 years (surgery)11 years/yes(13)
 Konstantinidis et al, 201912/FFrontal lobeVisual problems, headachesCystic component,STREMA+, desmin+ EWSR1/CREMNone28 months28 months/yes(13)
Myxoid mesenchymalKao et al, 201715/FMeningesNMNMNMEMA+, desmin+ EWSR1/CREMNoneNA17 months/none(14)
AFHKao et al, 201723/FMeninges (occipital)NMNMNMEMA+, desmin+ EWSR1/CREB1NoneNMNM(14)
 Kao et al, 201720/MFrontal lobeNMNMNMEMA+, desmin+ EWSR1/CREB1NoneNMNM(14)
 Kao et al, 201712/MFrontal lobeSeizuresNMNMEMA+, desmin- EWSR1/ATF1NoneNMNM(14)
 Bale et al, 201812/MPosterior cerebellar fossaHeadachesHeterogeneously enhancementSTREMA+, desmin+ EWSR1/CREB1NoneNA12 months/none(17)
 Bale et al, 201814/F IntraventricularHeadaches, visual problemsHeterogeneously enhancement, edemaSTREMA+, desmin+ EWSR1/CREB1NoneNA12 months/none(17)
 Bale et al, 201818/MFrontal lobeSeizuresEnhancement, edemaSTREMA+, desmin+ EWSR1/CREMNoneNA12 months/none(17)
 Sciot et al, 201817/FFrontal lobeHemiparesis, seizuresCystic component, minimal enhancementGTREMA+, desmin- EWSR1/ATF1RT after 2nd surgery3 months (surgery and RT)7 years/two(16)
 Gareton et al, 201819/MTentorium cerebelliSeizuresNMGTREMA+, desmin- EWSR1/CREM6 API/AI and RT10 years10 years/yes(15)
 Spatz et al, 201822/FOccipital lobeVisual problems, headaches, seizureHeterogeneously enhancement, edemaSTREMA+, desmin+NMNoneNA3 months/none(23)
 Ghanbari et al, 201958/FParafalcineSeizureHomogenous enhancement, edemaSTREMA+, desmin+ EWSR1/CREB1NoneNA3 months/none(18)
 Gunness et al, 201932/FTemporal lobeHeadachesCystic component, heterogeneously enhancementSTRNMNMNone1 year (surgery)2 years/yes(19)
 White et al, 20199/MFrontal lobeFatigue, abuliaCystic component, enhancementGTR Desmin+/-, EMA NM EWSR1/CREMNone6 months (surgery and RT)6 months/yes(20)
 Ballester et al, 202067/MTemporal lobeAphasia, confusionCystic component, enhancement, edemaSTREMA+, desmin+ EWSR1/ATF1NoneNA3.5 months/none(21)
 Komatsu et al, 202053/FThird ventricleHeadache, dizzinessHomogenous enhancementSTREMA+, desmin+ EWSR1/CREB1GKSNA3 months/none(22)

[i] aGKS after 4 surgeries and then after 3 other surgeries;

[ii] bdied after 9 surgeries and 2 GKS. API, doxorubicin-ifosfamide-cisplatin-based regimen; AI, doxorubicin-ifosfamide-based regimen; AFH, angiomatoid fibrous histiocytoma; EMA, epithelial membrane antigen; F, female; GKS, gamma knife surgery; GTR, gross total resection; IHC, immunohistochemistry; M, male; NA, not applicable; NM, not mentioned; RT, radiotherapy; STR, subtotal resection.

All the reports support gross total resection as the gold standard treatment at presentation and recurrence. Indeed there is a lack of proof regarding radiotherapy and chemotherapy. In metastatic soft tissue AFH, anthracycline based chemotherapy has previously been used successfully in two cases suggesting the likely usefulness of such treatment in patient with unresectable and/or metastatic disease (26,27). Also, one of the latest case reports of intracranial AFH suggests that use of chemotherapy as an adjuvant therapy could be considered if surgical resection was vain or deleterious to the patient (13). Actually, one patient was treated with 6 cycles of API/AI type chemotherapy but it was for a myxoid-variant AFH and after complete tumor removal. None of the patients presented in the cases was challenged with chemotherapy at tumor progression.

This case report confirms that the diagnostic of intracranial AFH can be problematic and a gross total resection, when possible, must be considered. Besides, an integrated approach using morphology, immunohistochemistry and molecular analysis is recommended to support the diagnosis of this rare entity. The potential relation with the myxoid component needs to be further studied. Treatments options after surgery for recurrent or progressive intracranial AFH, myxoid or not, are scarce and the optimal treatment sequence is unknown. Here we present the first case of intracranial conventional AFH with EWSR1/CREB1 fusion transcript, treated with doxorubicin at progression, inducing prolonged stable disease fourteen months after treatment discontinuation.

In conclusion, in the absence of gold standard management for such cases, the present case suggests that chemotherapy should be considered in intracranial AFH when surgery is not an option. Desmin staining and EWSR1 gene fusions should be searched for in all cases possibly compatible with intracranial AFH especially in EMA positive spindle cell tumors without typical meningioma features. A single institute observational study is currently ongoing in Italy. All the medical records, radiological imaging, and histological slides are being reviewed to identify the best therapeutic approach (NCT03759327). Moreover, radiation therapy with or without chemotherapy combination (including doxorubicin) or targeted therapy before surgery are currently being explored for patients with newly diagnosed non-rhabdomyosarcoma soft tissue sarcomas (comprising AFH) (NCT02180867), which could give us clues to the best treatment for intracranial AFH patients.

Acknowledgements

Not applicable.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

LG instructed and participated in the treatment of the patient, performed the literature search, and mainly wrote the manuscript. LG and TF created the figures and tables. JH and FD instructed and participated in the treatment of the patient. TF, JH and FD provided critical revisions of the manuscript for important intellectual content. TF, DM and DP carefully reviewed the pathological findings. RA carefully reviewed the radiology findings. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The patient provided written informed consent prior to treatment.

Patient consent for publication

Written informed consent was obtained from the patient for publication of this case report and any accompanying images.

Competing interests

The authors declare that they have no competing interests.

References

1 

Lemaigre FP, Ace CI and Green MR: The cAMP response element binding protein, CREB, is a potent inhibitor of diverse transcriptional activators. Nucleic Acids Res. 21:2907–2911. 1993.PubMed/NCBI View Article : Google Scholar

2 

Gonzalez GA and Montminy MR: Cyclic AMP stimulates somatostatin gene transcription by phosphorylation of CREB at serine 133. Cell. 59:675–680. 1989.PubMed/NCBI View Article : Google Scholar

3 

Thway K and Fisher C: Tumors with EWSR1-CREB1 and EWSR1-ATF1 fusions: The current status. Am J Surg Pathol. 36(11)2012.PubMed/NCBI View Article : Google Scholar

4 

Enzinger FM: Angiomatoid malignant fibrous histiocytoma. A distinct fibrohistiocytic tumor of children and young adults simulating a vascular neoplasm. Cancer. 44:2147–2157. 1979.PubMed/NCBI View Article : Google Scholar

5 

Antonescu CR and Rossi S: WHO Classification of Tumours of Soft Tissue and Bone. Vol 5. 4th edition. Fletcher CD, Bridge JA, Hogendoorn PC and Mertens F (eds). IARC, Lyon, pp204-205, 2013.

6 

Saito K, Kobayashi E, Yoshida A, Araki Y, Kubota D, Tanzawa Y, Kawai A, Yanagawa T, Takagishi K and Chuman H: Angiomatoid fibrous histiocytoma: A series of seven cases including genetically confirmed aggressive cases and a literature review. BMC Musculoskelet Disord. 18(31)2017.PubMed/NCBI View Article : Google Scholar

7 

Fanburg-Smith JC and Miettinen M: Angiomatoid ‘malignant’ fibrous histiocytoma: A clinicopathologic study of 158 cases and further exploration of the myoid phenotype. Hum Pathol. 30:1336–1343. 1999.PubMed/NCBI View Article : Google Scholar

8 

Huret JL: EWSR1 (Ewing sarcoma breakpoint region 1). Atlas Genet Cytogenet Oncol Haematol. 15:395–407. 2011.

9 

Dunham C, Hussong J, Seiff M, Pfeifer J and Perry A: Primary Intracerebral angiomatoid fibrous histiocytoma: Report of a case with a t(12;22)(q13;q12) causing type 1 fusion of the EWS and ATF-1 genes. Am J Surg Pathol. 32:478–484. 2008.PubMed/NCBI View Article : Google Scholar

10 

Ochalski PG, Edinger JT, Horowitz MB, Stetler WR, Murdoch GH, Kassam AB and Engh JA: Intracranial angiomatoid fibrous histiocytoma presenting as recurrent multifocal intraparenchymal hemorrhage. J Neurosurg. 112:978–982. 2010.PubMed/NCBI View Article : Google Scholar

11 

Hansen JM, Larsen VA, Scheie D, Perry A and Skjøth-Rasmussen J: Primary intracranial angiomatoid fibrous histiocytoma presenting with anaemia and migraine-like headaches and aura as early clinical features. Cephalalgia. 35:1334–1336. 2015.PubMed/NCBI View Article : Google Scholar

12 

Alshareef MA, Almadidy Z, Baker T, Perry A, Welsh CT and Vandergrift WA III: Intracranial angiomatoid fibrous histiocytoma: Case report and literature review. World Neurosurg. 96:403–409. 2016.PubMed/NCBI View Article : Google Scholar

13 

Konstantinidis A, Cheesman E, O'Sullivan J, Pavaine J, Avula S, Pizer B and Kilday JP: Intracranial angiomatoid fibrous histiocytoma with EWSR1-CREB family fusions: A report of 2 pediatric cases. World Neurosurg. 126:113–119. 2019.PubMed/NCBI View Article : Google Scholar

14 

Kao YC, Sung YS, Zhang L, Chen CL, Vaiyapuri S, Rosenblum MK and Antonescu CR: EWSR1 fusions with CREB family transcription factors define a novel myxoid mesenchymal tumor with predilection for intracranial location. Am J Surg Pathol. 41:482–490. 2017.PubMed/NCBI View Article : Google Scholar

15 

Gareton A, Pierron G, Mokhtari K, Tran S, Tauziède-Espariat A, Pallud J, Louvel G, Meary E, Capelle L, Chrétien F and Varlet P: ESWR1-CREM fusion in an intracranial myxoid angiomatoid fibrous histiocytoma-like tumor: A case report and literature review. J Neuropathol Exp Neurol. 77:537–541. 2018.PubMed/NCBI View Article : Google Scholar

16 

Sciot R, Jacobs S, Calenbergh FV, Demaerel P, Wozniak A and Debiec-Rychter M: Primary myxoid mesenchymal tumour with intracranial location: Report of a case with a EWSR1-ATF1 fusion. Histopathology. 72:880–883. 2018.PubMed/NCBI View Article : Google Scholar

17 

Bale TA, Oviedo A, Kozakewich H, Giannini C, Davineni PK, Ligon K and Alexandrescu S: Intracranial myxoid mesenchymal tumors with EWSR1-CREB family gene fusions: Myxoid variant of angiomatoid fibrous histiocytoma or novel entity? Brain Pathol. 28:183–191. 2018.PubMed/NCBI View Article : Google Scholar

18 

Ghanbari N, Lam A, Wycoco V and Lee G: Intracranial myxoid variant of angiomatoid fibrous histiocytoma: A case report and literature review. Cureus. 11(e4261)2019.PubMed/NCBI View Article : Google Scholar

19 

Gunness VR, Munoz I, González-López P, Alshafai N, Mikalkova A and Spears J: Intracranial angiomatoid fibrous histiocytoma with Hodgkin lymphoma. Med J Malaysia. 74:234–236. 2019.PubMed/NCBI

20 

White MD, McDowell MM, Pearce TM, Bukowinski AJ and Greene S: Intracranial Myxoid mesenchymal tumor with rare EWSR1-CREM translocation. Pediatr Neurosurg. 54:347–353. 2019.PubMed/NCBI View Article : Google Scholar

21 

Ballester LY, Meis JM, Lazar AJ, Prabhu SS, Hoang KB, Leeds NE and Fuller GN: Intracranial myxoid mesenchymal tumor with EWSR1-ATF1 Fusion. J Neuropathol Exp Neurol. 79:347–351. 2020.PubMed/NCBI View Article : Google Scholar

22 

Komatsu M, Yoshida A, Tanaka K, Matsuo K, Sasayama T, Kojita Y, Kanda T, Kodama Y, Itoh T and Hirose T: Intracranial myxoid mesenchymal tumor with EWSR1-CREB1 gene fusion: A case report and literature review. Brain Tumor Pathol. 37:76–80. 2020.PubMed/NCBI View Article : Google Scholar

23 

Spatz M, Nussbaum ES, Lyons L, Greenberg S, Kallmes KM and Nussbaum LA: Primary intracranial angiomatoid fibrous histiocytoma: A case report and literature review. Br J Neurosurg: Mar 15, 2018 (Epub ahead of print). doi: 10.1080/02688697.2018.1451823.

24 

Antonescu CR, Dal Cin P, Nafa K, Teot LA, Surti U, Fletcher CD and Ladanyi M: EWSR1-CREB1 is the predominant gene fusion in angiomatoid fibrous histiocytoma. Genes Chromosomes Cancer. 46:1051–1060. 2007.PubMed/NCBI View Article : Google Scholar

25 

Thway K and Fisher C: Angiomatoid fibrous histiocytoma: The current status of pathology and genetics. Arch Pathol Lab Med. 139:674–682. 2015.PubMed/NCBI View Article : Google Scholar

26 

Ogden S, Harave S, McPartland J, Brennan B, Jeys L, Losty P and Pizer B: Angiomatoid fibrous histiocytoma: A case of local recurrence and metastases to loco-regional lymph nodes that responded to chemotherapy. Pediatr Blood Cancer: 64, 2017 doi: 10.1002/pbc.26376.

27 

Bernini JC, Fort DW, Pritchard M, Rogers BB and Winick NJ: Adjuvant chemotherapy for treatment of unresectable and metastatic angiomatoid malignant fibrous histiocytoma. Cancer. 74:962–964. 1994.PubMed/NCBI View Article : Google Scholar

Related Articles

Journal Cover

July-2021
Volume 15 Issue 1

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Garnier L, Fenouil T, Pissaloux D, Ameli R, Ducray F, Meyronet D and Honnorat J: Intracranial non‑myxoid angiomatoid fibrous histiocytoma with <em>EWSR1‑CREB1</em> transcript fusion treated with doxorubicin: A case report. Mol Clin Oncol 15: 131, 2021
APA
Garnier, L., Fenouil, T., Pissaloux, D., Ameli, R., Ducray, F., Meyronet, D., & Honnorat, J. (2021). Intracranial non‑myxoid angiomatoid fibrous histiocytoma with <em>EWSR1‑CREB1</em> transcript fusion treated with doxorubicin: A case report. Molecular and Clinical Oncology, 15, 131. https://doi.org/10.3892/mco.2021.2293
MLA
Garnier, L., Fenouil, T., Pissaloux, D., Ameli, R., Ducray, F., Meyronet, D., Honnorat, J."Intracranial non‑myxoid angiomatoid fibrous histiocytoma with <em>EWSR1‑CREB1</em> transcript fusion treated with doxorubicin: A case report". Molecular and Clinical Oncology 15.1 (2021): 131.
Chicago
Garnier, L., Fenouil, T., Pissaloux, D., Ameli, R., Ducray, F., Meyronet, D., Honnorat, J."Intracranial non‑myxoid angiomatoid fibrous histiocytoma with <em>EWSR1‑CREB1</em> transcript fusion treated with doxorubicin: A case report". Molecular and Clinical Oncology 15, no. 1 (2021): 131. https://doi.org/10.3892/mco.2021.2293